TRIUMPH-2
retatrutide yields up to 18.8 percent weight loss and a 10.8 mmHg lower systolic blood pressure in obesity with type 2 diabetes, with hypotension and dysesthesia as new signals
Presented at EASD 2026 in Milan and published simultaneously in The Lancet. TRIUMPH-2 randomised 1,152 adults with obesity or overweight (BMI 27 or higher, mean 38.2) and type 2 diabetes (mean HbA1c 7.7 percent) to once-weekly retatrutide 4, 9 or 12 mg or placebo for 80 weeks at 92 sites in eight countries. Body weight changed by -11.9, -16.8 and -18.8 percent versus -5.1 percent with placebo (treatment-regimen estimand; differences -6.9 to -13.8 points, all p below 0.0001); HbA1c fell by 1.4 to 1.6 points versus 0.2. At 12 mg, systolic blood pressure fell 10.8 mmHg, triglycerides 39.5 percent, non-HDL cholesterol 19.6 percent and hsCRP 58.3 percent (sponsor data). Gastrointestinal events dominated; hypotension (1 to 6 percent versus below 1) and dysesthesia (4 to 7 versus 1 percent) were more frequent with retatrutide; discontinuation for adverse events or death was 4, 12 and 8 percent versus 5. Seven deaths (six on retatrutide), judged unrelated. No outcome data yet; Lilly plans a US submission in Q1 2027.
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.
